The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1638
Two New Pneumococcal Vaccines - Prevnar 20 and Vaxneuvance

This article is no longer freely available.

Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Two New Pneumococcal Vaccines - Prevnar 20 and Vaxneuvance
The FDA has licensed two new pneumococcal conjugate vaccines (PCVs) for prevention of invasive pneumococcal disease in adults: Prevnar 20 (PCV20; Pfizer), which contains antigens from 20 serotypes of pneumococcus, and Vaxneuvance (PCV15;...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Two New Pneumococcal Vaccines - Prevnar 20 and Vaxneuvance
Article code: 1638c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.